Navigation Links
Oxygen Biotherapeutics, Inc. Signs Cooperative Research and Development Agreement With Naval Medical Research Center and Walter Reed Army Institute of Research

COSTA MESA, Calif., May 13 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced that the company has signed a Limited Purpose Cooperative Research and Development Agreement (LP-CRADA) with the Naval Medical Research Center (NMRC) and the Walter Reed Army Institute of Research (WRAIR), Federal laboratories of the United States Department of Defense.

Under the agreement the company would provide information that would be used by NMRC and WRAIR for preparation, writing, and submission to the FDA of an Investigational New Drug (IND) application for the use of Oxycyte(R) for the treatment of decompression sickness. Oxycyte is the company's perfluorocarbon (PFC) therapeutic oxygen carrier.

For more color on what this agreement means to the company, please read today's blog by Oxygen Biotherapeutics, Inc. chairman and CEO, Chris Stern, which can be accessed via the Shareholder Forum link on the Investor Relations page of the company website at It can also be accessed directly by pasting the following link into a web browser:

About the Walter Reed Army Institute of Research

Walter Reed Army Institute of Research is the largest, most diverse, and oldest laboratory in the US Army Medical Research and Material Command. It conducts research on a range of military relevant issues, including naturally occurring infectious diseases, combat casualty care, operational health hazards, and medical defense against biological and chemical weapons. WRAIR is the Department of Defense's lead agency for infectious disease research and a crucial source of research support for medical product development.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has under development a perfluorocarbon therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs and medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis pain, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes and cosmetic applications. More information is available at

SOURCE Oxygen Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Oxygen Biotherapeutics, Inc. Files Cosmetic Product Ingredient Statement for new Oxycyte-based Cosmetic Gel
2. Turtle Island Oxygen Trust Sponsors Free Hyperbaric Treatments
3. G & G Holistic Addiction Treatment Uses Innovative Use of Oxygen Therapy Which Restores Mind and Body in Drug Rehab
4. Octi-Flo2™ - 8 Patient Portable Oxygen Delivery System
5. House Republican Leader Boehner Says CMS Policies on Home Oxygen Therapy Will Potentially Harm Care Available to Medicare Beneficiaries
6. Oxygen Biotherapeutics, Inc. Establishes Warfighter Division
7. Ozone/Oxygen Shot Helps Heal Herniated Disk
8. OxygenToGo Is Poised To Help Airlines Struggling With New Portable Oxygen Concentrator Regulations From The U.S. DOT
9. Oxygen4Energy: International Sports News - World Anti-Doping Agency (WADA) Bans Oxygen Use
10. Calling Policies Unreasonable, 123 Members of Congress Press for Changes in Medicare Home Oxygen Policies for Emergency Care, Supplies and Other Obligations After 36 Months of Service
11. An atmosphere rich in CO2 and oxygen enhances the quality of refrigerated potato
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... ... optimization of adjunctive imaging is the focus of numerous abstracts accepted for presentation ... 29-December 4, 2015. Nine abstracts highlight the use of Volpara Solutions’ quantitative ...
(Date:12/1/2015)... ... December 01, 2015 , ... SAN FRANCISCO, Calif. (December ... the organization has awarded Education and Developmental Therapies (EDT), an Applied Behavior Analysis ... celebrates exceptional special needs providers that excel in synthesizing the areas of clinical ...
(Date:12/1/2015)... ... December 01, 2015 , ... TCS Healthcare Technologies (TCS), a ... health arenas, is pleased to announce that VIP Care Services, a Caprock Health ... the ACUITY Complete Care™ Management to back their collaborative catastrophic case management initiatives. ...
(Date:12/1/2015)... ... December 01, 2015 , ... With FCPX Overlay: Grit , users ... over customization, the possibilities are truly endless, all with a click of a mouse. ... vertical flip, horizontal flip, depth of field and more, all within Final Cut Pro ...
(Date:12/1/2015)... ... December 01, 2015 , ... Tympani Inc., announced today ... status from Cisco. This designation recognizes Tympani as having fulfilled the training requirements ... targeted to the high-end enterprise contact center marketplace. , Ed Kapelinski, President of ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... and TELTOW, Germany , ... Instruments (SMI) , a leading global manufacturer of eye ... LLC has included SMI remote eye trackers as ... help healthcare providers assess concussions, eye sight, and medical ... RED -oem technology is part of SMI,s mass-market-ready eye ...
(Date:12/1/2015)... , December 1, 2015 ... Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-AVL), among ... has acquired Elekta,s Leksell Gamma Knife® Icon™, the ... brain. --> --> ... or traditional frame-based treatments, Leksell Gamma Knife Icon ...
(Date:12/1/2015)... 01, 2015 ... "Drug Delivery Technology Market 2015 - Forecast to ... ) has announced the addition of ... Forecast to 2020" report to their offering. ... ) has announced the addition of the ...
Breaking Medicine Technology: